Matrix metalloproteinase gene polymorphisms and susceptibility to systemic sclerosis

Genetics and Molecular Research

Volumn 15, Issue 4, 2016, Pages

  Rech, T F ^a   Moraes, S B C ^a   Bredemeier, M ^b   de Paoli, J ^a   Brenol, J C T ^c   Xavier, R M ^c   Chies, J A B ^d   Simon, D ^a  

^a UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^b HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Genetic polymorphisms; Matrix metalloproteinase; MMP1; MMP3; MMP9; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; CARBON MONOXIDE; GELATINASE B; INTERSTITIAL COLLAGENASE; SCLEROPROTEIN; STROMELYSIN; MMP1 PROTEIN, HUMAN; MMP3 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN;

ADULT; ARTICLE; CALCINOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MMP1 GENE; MMP3 GENE; MMP9 GENE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN DEGRADATION; SYSTEMIC SCLEROSIS; TELANGIECTASIA; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SCLERODERMA, SYSTEMIC;

EID: 85007484150     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/gmr15049077     Document Type: Article

References (35)

1. Abramson JH (2011). WINPEPI updated: computer programs for epidemiologists, and their teaching potential. Epidemiol. Perspect. Innov. 8: 1. http: //dx.doi.org/10.1186/1742-5573-8-1
2. Bahrehmand F, Vaisi-Raygani A, Kiani A, Rahimi Z, et al. (2015). Matrix metalloproteinase 9 polymorphisms and systemic lupus erythematosus: correlation with systemic inflammatory markers and oxidative stress. Lupus 24: 597-605. http: //dx.doi.org/10.1177/0961203314559085
3. Bhattacharyya S, Wei J and Varga J (2011). Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat. Rev. Rheumatol. 8: 42-54. http: //dx.doi.org/10.1038/nrrheum.2011.149
4. Bredemeier M, Xavier RM, Capobianco KG, Restelli VG, et al. (2004). Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis. J. Rheumatol. 31: 286-294.
5. Brown M, Postlethwaite AE, Myers LK and Hasty KA (2012). Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts. Clin. Rheumatol. 31: 973-981. http: //dx.doi.org/10.1007/s10067-012-1962-z
6. Chaudhary AK, Singh M, Bharti AC, Singh M, et al. (2010). Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions. BMC Cancer 10: 369.http: //dx.doi.org/10.1186/1471-2407-10-369
7. Dunleavey L, Beyzade S and Ye S (2000a). Rapid genotype analysis of the matrix metalloproteinase-1 gene 1G/2G polymorphism that is associated with risk of cancer. Matrix Biol. 19: 175-177. http: //dx.doi.org/10.1016/S0945-053X (00) 00059-7
8. Dunleavey L, Beyzade S and Ye S (2000b). Rapid genotype analysis of the stromelysin gene 5A/6A polymorphism. Atherosclerosis 151: 587-589. http: //dx.doi.org/10.1016/S0021-9150 (00) 00443-3
9. Frost J, Ramsay M, Mia R, Moosa L, et al. (2012). Differential gene expression of MMP-1, TIMP-1 and HGF in clinically involved and uninvolved skin in South Africans with SSc. Rheumatology (Oxford) 51: 1049-1052. http: //dx.doi.org/10.1093/rheumatology/ker367
10. Graf SW, Hakendorf P, Lester S, Patterson K, et al. (2012). South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int. J. Rheum. Dis. 15: 102-109. http: //dx.doi.org/10.1111/j.1756-185X.2011.01688.x
11. Gutierrez Jr A and Wetter DA (2012). Calcinosis cutis in autoimmune connective tissue diseases. Dermatol. Ther. (Heidelb.) 25: 195-206. http: //dx.doi.org/10.1111/j.1529-8019.2012.01492.x
12. Hamaguchi Y (2010). Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J. Dermatol. 37: 42-53. http: //dx.doi.org/10.1111/j.1346-8138.2009.00762.x
13. Jiang S, Yang ZH, Chen YY, He Z, et al. (2016). MMP-9 genetic polymorphism may confer susceptibility to COPD. Genet. Mol. Res. 15: gmr6272. http: //dx.doi.org/10.4238/gmr.15026272
14. Johnson RW, Reveille JD, McNearney T, Fischbach M, et al. (2001). Lack of association of a functionally relevant single nucleotide polymorphism of matrix metalloproteinase-1 promoter with systemic sclerosis (scleroderma). Genes Immun. 2: 273-275. http: //dx.doi.org/10.1038/sj.gene.6363768
15. Katsumoto TR, Whitfield ML and Connolly MK (2011). The pathogenesis of systemic sclerosis. Annu. Rev. Pathol. 6: 509-537. http: //dx.doi.org/10.1146/annurev-pathol-011110-130312
16. Kikuchi K, Kubo M, Hoashi T and Tamaki K (2002). Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis. Clin. Exp. Dermatol. 27: 301-305. http: //dx.doi.org/10.1046/j.1365-2230.2002.01011.x
17. Lahiri DK and Nurnberger Jr JI (1991). A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 19: 5444. http: //dx.doi.org/10.1093/nar/19.19.5444
18. LeRoy EC and Medsger Jr TA (2001). Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28: 1573-1576.
19. Luo Y, Wang Y, Wang Q, Xiao R, et al. (2013). Systemic sclerosis: genetics and epigenetics. J. Autoimmun. 41: 161-167. http: //dx.doi.org/10.1016/j.jaut.2013.01.012
20. Ma MJ, Liu HC, Qu XQ and Wang JL (2015). Matrix metalloproteinase-3 gene polymorphism and its mRNA expression in rheumatoid arthritis. Genet. Mol. Res. 14: 15652-15659. http: //dx.doi.org/10.4238/2015.December.1.17
21. Ma YZ, Jiang QY and Kong DQ (2016). Association between matrix metallopeptidase 1 and type 2 diabetes mellitus coexisting with coronary heart disease in a Han Chinese population. Genet. Mol. Res. 15: gmr.15027938
22. Marasini B, Casari S, Zeni S, Turri O, et al. (2001). Stromelysin promoter polymorphism is associated with systemic sclerosis. Rheumatology (Oxford) 40: 475-476. http: //dx.doi.org/10.1093/rheumatology/40.4.475
23. Meng C, Chen X, Li J, Wu Y, et al. (2008). Expression of MMP-9 and TIMP-1 in lesions of systemic sclerosis and its implications. J. Huazhong Univ. Sci. Technolog. Med. Sci. 28: 480-482. http: //dx.doi.org/10.1007/s11596-008-0424-y
24. Morgan AR, Zhang B, Tapper W, Collins A, et al. (2003). Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J. Mol. Med. (Berl.) 81: 321-326. http: //dx.doi.org/10.1007/s00109-003-0441-z
25. Murphy G (2011). Tissue inhibitors of metalloproteinases. Genome Biol. 12: 233. http: //dx.doi.org/10.1186/gb-2011-12-11-233
26. Murray LA, Rubinowitz A and Herzog EL (2012). Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease? Curr. Opin. Rheumatol. 24: 656-662. http: //dx.doi.org/10.1097/BOR.0b013e3283588de4
27. Peng WJ, Yan JW, Wan YN, Wang BX, et al. (2012). Matrix metalloproteinases: a review of their structure and role in systemic sclerosis. J. Clin. Immunol. 32: 1409-1414. http: //dx.doi.org/10.1007/s10875-012-9735-7
28. Robert S, Gicquel T, Victoni T, Valença S, et al. (2016). Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosis. Biosci. Rep. 36: e00360. http: //dx.doi.org/10.1042/BSR20160107
29. Rosas IO, Richards TJ, Konishi K, Zhang Y, et al. (2008). MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 5: e93. http: //dx.doi.org/10.1371/journal.pmed.0050093
30. Scherer S, de Souza TB, de Paoli J, Brenol CV, et al. (2010). Matrix metalloproteinase gene polymorphisms in patients with rheumatoid arthritis. Rheumatol. Int. 30: 369-373. http: //dx.doi.org/10.1007/s00296-009-0974-8
31. Schirmer H, Basso da Silva L, Teixeira PJ, Moreira JS, et al. (2009). Matrix metalloproteinase gene polymorphisms: lack of association with chronic obstructive pulmonary disease in a Brazilian population. Genet. Mol. Res. 8: 1028-1034. http: //dx.doi.org/10.4238/vol8-3gmr596
32. Skarmoutsou E, D’Amico F, Marchini M, Stivala F, et al. (2011). Analysis of matrix metalloproteinase-9 gene polymorphism-1562 C/T in patients suffering from systemic sclerosis with and without ulcers. Int. J. Mol. Med. 27: 873-877. http: //dx.doi.org/10.3892/ijmm.2011.661
33. Toubi E, Kessel A, Grushko G, Sabo E, et al. (2002). The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin. Exp. Rheumatol. 20: 221-224.
34. Varga J and Abraham D (2007). Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Invest. 117: 557-567. http: //dx.doi.org/10.1172/JCI31139
35. Young-Min SA, Beeton C, Laughton R, Plumpton T, et al. (2001). Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud’s phenomenon, and in normal controls. Ann. Rheum. Dis. 60: 846-851.